challenges in distinguishing between pre-mds states and mds, and approaches to improve diagnosis
Published 1 year ago • 197 plays • Length 3:01Download video MP4
Download video MP3
Similar videos
-
4:25
the challenges with accurately diagnosing and risk-stratifying patients with mds
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
3:17
pre-mds states: novel therapeutic approaches, and determining appropriate trial endpoints
-
1:22
key advances in mds management
-
2:33
what can artificial intelligence bring to the diagnosis and management of mds?
-
3:31
relevance of the ipss-r during sct in patients with mds in the molecular classification era
-
2:52
long-term evaluation of luspatercept in esa-intolerant/refractory lr-mds: medalist follow-up study
-
1:17
phase ii study of tosedostat in mds
-
1:29
automated tool for mds classification using the who & icc classification systems
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
4:31
labmt: impact of treatment prior to allogenic hct in mds
-
3:16
developing patient-specific mrd markers for predicting and preventing mds relapse post-sct
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
2:06
outcomes & promising treatment options following hma failure in patients with hr-mds
-
2:04
state-of-the-art treatment for hr-mds
-
2:12
allosct for aml with mds-related features as per the icc and who 2022 classifications
-
1:36
clinical trials evaluating novel agents in mds: select-mds-1
-
1:14
insights into the management of mds/mpn overlap syndromes & advice for clinicians
-
1:45
a phase ii study of elritercept for lower-risk mds